Infectious Diseases Molecular Diagnostics Kit Market, valued at USD 18.2 billion in 2024, is projected to expand significantly to USD 31.05 billion by 2031, registering a robust CAGR of 8.1% during 2024–2031. As infectious disease burdens intensify globally and diagnostic accuracy becomes central to clinical decision-making, molecular diagnostics kits are emerging as essential tools across hospitals, diagnostic laboratories, and public health systems. This market’s rapid rise underscores its critical importance in the broader healthcare and life sciences landscape, particularly amid increasing emphasis on precision diagnostics, pathogen surveillance, and outbreak preparedness.
Preview Market Insights with a Free Sample Report https://www.24lifesciences.com/download-sample/5574/infectious-diseases-molecular-diagnostics-kit-market
Market Highlights & Segmentation Analysis
By Type
PCR-based kits remain the dominant segment due to their reliability, affordability, and widespread clinical use. PCR continues to serve as the “gold standard” for pathogen detection—including influenza, HIV, RSV, tuberculosis, and emerging viral threats—owing to its unmatched specificity. NGS-based kits are gaining traction as healthcare systems focus on genomic surveillance, variant tracking, and high-throughput applications. Hybridization-based kits maintain relevance for specific molecular assays but account for a smaller market share.
By Application
The respiratory infections segment leads the market’s growth trajectory. The persistent need for accurate testing of COVID-19, influenza, RSV, and other respiratory pathogens has strengthened adoption of multiplex molecular diagnostic panels. Testing for sexually transmitted infections (STIs), bloodborne infections, and gastrointestinal infections remains stable, supported by rising screening programs, expanded public health funding, and improved laboratory infrastructure worldwide.
By End User
Hospitals and diagnostic labs comprise the largest end-user segment, driven by high testing volumes, rapid turnaround demands, and integration with laboratory information systems (LIS). Academic and research institutes contribute significantly to innovation, while public health laboratories rely on molecular kits for disease surveillance, outbreak investigations, and epidemiological monitoring.
Unlock Comprehensive Market Analysis Here https://www.24lifesciences.com/infectious-diseases-molecular-diagnostics-kit-market-5574
Key Market Drivers
- Increased global prevalence of infectious diseases including re-emerging viral infections and antimicrobial-resistant pathogens.
- Technological advancement in PCR, multiplex assays, and rapid molecular platforms.
- Public health initiatives focused on pandemic preparedness and early detection.
- Rising demand for point-of-care molecular diagnostics to accelerate clinical decision-making.
- Strengthening regulatory support for advanced diagnostics during health emergencies.
Emerging Trends Shaping the Healthcare Market
The infectious disease diagnostics sector is being reshaped by AI-enabled analytics, precision medicine, and digital health integration. AI-driven diagnostic workflows are improving test interpretation and reducing laboratory workload. Next-generation sequencing (NGS) supports real-time pathogen surveillance, while digital platforms streamline data reporting and remote monitoring. These innovations are expected to accelerate molecular diagnostics adoption through 2032 as healthcare providers pivot to faster, more accurate, and scalable testing modalities
Key Players & Competitive Landscape
The market is characterized by strong competition and continuous innovation. Major companies are expanding product pipelines, enhancing distribution networks, and investing in next-generation testing solutions.
Leading Companies Include:
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- QIAGEN N.V.
- bioMérieux S.A.
- Danaher Corporation (Cepheid)
- Becton, Dickinson and Company (BD)
- Thermo Fisher Scientific Inc.
- Siemens Healthineers
- Hologic Inc.
Unlock Comprehensive Market Analysis Here https://www.24lifesciences.com/infectious-diseases-molecular-diagnostics-kit-market-5574
Forward View
The Infectious Diseases Molecular Diagnostics Kit Market is set for sustained expansion driven by:
- Increasing global disease surveillance programs
- Need for rapid and accurate molecular testing
- Growth of NGS adoption in public health
- Expansion of point-of-care molecular systems
- Rising clinical demand for multiplex diagnostic panels
The market’s expected growth to USD 31.05 billion by 2031 reflects its central role in shaping the future of infectious disease management, outbreak response, and precision diagnostic
Explore our related reports
About 24lifesciences
Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market
International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)
Website: www.24lifesciences.com
Follow us on LinkedIn: www.linkedin.com/company/lifesciences24
- Single-Domain Heavy Chain Antibody Market - 2026-01-23
- Qianlie Antong Capsules Market - 2026-01-23
- Veterinary Amitraz Solution Market - 2026-01-23